Procyon Advisors
VRTX icon

Procyon Advisors’s Vertex Pharmaceuticals VRTX Stock Holding History

Procyon Advisors’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$1.39M Sell
2,664
-260
-9% -$133K 0.06% 236
2026
Q2 		$1.45M Sell
2,924
-285
-9% -$126K 0.06% 234
2026
Q1 		$1.43M Buy
3,209
+3
+0.1% +$1.4K 0.07% 228
2025
Q4 		$1.45M Sell
3,206
-139
-4% -$59.9K 0.07% 221
2025
Q3 		$1.31M Sell
3,345
-1,083
-24% -$453K 0.08% 203
2025
Q2 		$1.97M Sell
4,428
-14,170
-76% -$6.53M 0.18% 107
2025
Q1 		$9.02M Buy
18,598
+3,963
+27% +$1.85M 0.55% 42
2024
Q4 		$5.89M Sell
14,635
-375
-2% -$174K 0.37% 57
2024
Q3 		$6.98M Buy
15,010
+157
+1% +$75.4K 0.48% 47
2024
Q2 		$6.96M Buy
14,853
+530
+4% +$230K 0.52% 48
2024
Q1 		$5.99M Buy
14,323
+636
+5% +$269K 0.46% 52
2023
Q4 		$5.57M Buy
13,687
+939
+7% +$347K 0.47% 45
2023
Q3 		$4.43M Buy
12,748
+5,375
+73% +$1.88M 0.45% 51
2023
Q2 		$2.59M Buy
7,373
+4,028
+120% +$1.36M 0.33% 72
2023
Q1 		$1.05M Buy
3,345
+643
+24% +$193K 0.18% 127
2022
Q4 		$780K Buy
2,702
+1,424
+111% +$434K 0.14% 148
2022
Q3 		$370K Sell
1,278
-88
-6% -$25.3K 0.09% 205
2022
Q2 		$385K Buy
1,366
+37
+3% +$9.9K 0.08% 218
2022
Q1 		$347K Buy
+1,329
New +$315K 0.07% 236
2020
Q3 		– Sell
-272
Closed -$79K – 1031
2020
Q2 		$79K Hold
272
– – 0.04% 322
2020
Q1 		$65K Hold
272
– – 0.04% 301
2019
Q4 		$60K Buy
+272
New +$55K 0.04% 327

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $824B AUM 37.44% 1-Year Est. Return
BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $704B AUM 26.74% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.27T AUM 50.62% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.84T AUM 33.86% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $483B AUM 27.72% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM

Procyon Advisors's VRTX Position: Q3 2026 in Review

Procyon Advisors reduced its Vertex Pharmaceuticals (VRTX) stake by 8.9% in Q3 2026, selling an estimated $133K and leaving 2,664 shares worth $1.39M. The position accounts for 0.06% of the portfolio, ranked #236.

Procyon Advisors first reported a position in VRTX in Q4 2019 and has held it in 22 quarters since. The position peaked at $9.02M in Q1 2025. 1,556 funds tracked by Wall St. Rank hold VRTX as of Q3 2026.

  • Procyon Advisors held 2,664 shares of Vertex Pharmaceuticals worth $1.39M as of Q3 2026.
  • Procyon Advisors sold 260 Vertex Pharmaceuticals shares in Q3 2026, an estimated $133K.
  • Vertex Pharmaceuticals made up 0.06% of Procyon Advisors's portfolio in Q3 2026, its #236 holding.
  • Procyon Advisors first reported a position in Vertex Pharmaceuticals in Q4 2019 and has held it in 22 quarters since.
  • Procyon Advisors's Vertex Pharmaceuticals position peaked at $9.02M in Q1 2025.
  • 1,556 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2026.

Based on Procyon Advisors's 13F filing for Q3 2026, filed 21 Oct 2026.